Sirnaomics Ltd. (HKG:2257)
Hong Kong · Delayed Price · Currency is HKD 3.675
-0.115 (-3.03%)
Sep 21, 2026, 2:02 PM HKT
Sirnaomics Revenue
Sirnaomics had revenue of $113.00K USD in the half year ending June 30, 2026, a decrease of -87.58%. This brings the company's revenue in the last twelve months to $32.00K, down -96.63% year-over-year.
Revenue (ttm)
$32.00K
Revenue Growth
-96.63%
P/S Ratio
1,644.68
Revenue / Employee
$864.86
Employees
37
Market Cap
412.73M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.78M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | 634.00K | 892.96% |
| Dec 31, 2021 | 71.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 549.77M |
| 3D Medicines | 412.66M |
| Cutia Therapeutics | 383.95M |
| JW (Cayman) Therapeutics Co. | 333.25M |
| Kintor Pharmaceutical | 90.90M |
| Wuhan YZY Biopharma | 72.52M |
| Shanghai Bio-heart Biological Technology | 44.39M |
| Brii Biosciences | 40.23M |
Sirnaomics News
- 23 days ago - Sirnaomics Earnings release: H1 2026 - Filings
- 5 months ago - Sirnaomics Earnings release: H2 2025 - Filings
- 5 months ago - Sirnaomics Annual report: H2 2025 - Filings
- 1 year ago - Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Benzinga